Tetraphase Pharmaceuticals
2006
FOUNDED
PUBLIC
STATUS
101-200
EMPLOYEES
TTPH
STOCK SYMBOL
$2.29
SHARE PRICE
(As of Friday Closing)
Description
Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is XERAVA (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 480 Arsenal Street
- Suite 110
- Watertown, MA 02472
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Tetraphase Pharmaceuticals’s full profile, request a free trial.
Tetraphase Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $2.06 - $33.40 | $6.91M | $2.25 | -$29.70 | 110K | 3.02M |
Tetraphase Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | (22,072) | (36,362) | 162,547 | (13,351) |
| Revenue | 9,970 | 18,904 | 9,666 | 5,145 |
| EBITDA | (77,958) | (72,705) | (115,284) | (77,198) |
| Net Income | (80,194) | (72,158) | (114,752) | (77,480) |
| Total Assets | 42,280 | 122,944 | 149,040 | 151,710 |
| Total Debt | 5,347 | 28,291 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Tetraphase Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Tetraphase Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookTetraphase Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is reserved for PitchBook Platform users. To explore Tetraphase Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookTetraphase Pharmaceuticals Competitors (23)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SCYNEXIS | Formerly VC-backed | Durham, NC | 00 | 00000 | 000000000 | 00000 |
| 00 000000000000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| 000000000 00000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000 - 000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 00000000 | 00.000 |
Tetraphase Pharmaceuticals Executive Team (12)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Larry Edwards | Chief Executive Officer & President | ||
| Maria Stahl | General Counsel & Executive | ||
| Erik Phillips | Executive |
9 Former Executives
You’re viewing 3 of 12 executives. Get the full list »Tetraphase Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Garen Bohlin | Self | Board Member | 000 0000 | |
| Guy Macdonald | Tetraphase Pharmaceuticals | Board Member | 000 0000 | |
| Jeffrey Chodakewitz MD | Self | Board Member | 000 0000 | |
| John Freund MD | Self | Board Member | 000 0000 | |
| Nancy Wysenski | Self | Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 12 board members. Get the full list »